| Oct 25 |
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma
|
| Oct 24 |
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
|
| Oct 21 |
Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update
|
| Oct 11 |
Wall Street Analysts Think Verona Pharma (VRNA) Could Surge 25.25%: Read This Before Placing a Bet
|
| Oct 9 |
Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why
|
| Oct 3 |
Verona started at overweight by Wells Fargo, says COPD drug undervalued
|
| Sep 30 |
Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024
|
| Sep 14 |
Verona Pharma's Ohtuvayre Set To Unlock Significant Value In COPD Care
|
| Sep 14 |
Insider Sale: CFO Mark Hahn Sells 600,000 Shares of Verona Pharma PLC (VRNA)
|
| Sep 14 |
Verona Pharma PLC (VRNA) CEO David Zaccardelli Sells 600,000 Shares
|
